SCHEMBL2971998

SCHEMBL2971998

O=C(O)c1c[nH]c2cccc(F)c2c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.55
HSD17B10 Q99714 1/20 0.55
KDM4E B2RXH2 3/20 0.51
FFAR1 O14842 1/20 0.47
GPR84 Q9NQS5 1/20 0.47
ALDH1A1 P00352 3/20 0.44
HPGD P15428 3/20 0.44
MEN1 O00255 1/20 0.44
ALOX12 P18054 1/20 0.44
KMT2A Q03164 1/20 0.44
HTR2A P28223 1/20 0.44
ALB P02768 2/20 0.43
MDH2 P40926 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CSNK2A2 P19784 2/20 0.41
CSNK2B P67870 2/20 0.41
CSNK2A1 P68400 2/20 0.41
IL2 P60568 1/20 0.41
DNA2 P51530 1/20 0.40
CASP6 P55212 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2034897 0.88 GPR84 (0.51) CYP1A2HSD17B10KDM4EFFAR1GPR84
SCHEMBL397484 0.82 CYP1A2 (0.56) CYP1A2HSD17B10KDM4EALDH1A1HPGD
SCHEMBL2309708 0.81 HSD17B10 (0.55) CYP1A2HSD17B10KDM4EGPR84ALDH1A1
SCHEMBL1353154 0.80 CYP1A2 (0.51) CYP1A2HSD17B10KDM4EALDH1A1HPGD
SCHEMBL1558360 0.79 HTR2A (0.49) KDM4EFFAR1GPR84ALDH1A1MEN1
SCHEMBL2285923 0.79 CLEC4M (0.55) CYP1A2HSD17B10KDM4EALDH1A1HPGD
SCHEMBL4650147 0.79 KDM4E (0.44) CYP1A2HSD17B10KDM4EALDH1A1HPGD
SCHEMBL10478117 0.78 CYP1A2 (0.56) CYP1A2HSD17B10KDM4EALDH1A1HPGD
SCHEMBL10366861 0.78 HSD17B10 (0.56) CYP1A2HSD17B10KDM4EALDH1A1HPGD
SCHEMBL9689318 0.77 CYP1A2 (0.51) CYP1A2HSD17B10KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140343098-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-11-20 US disclosed
US-8802700-B2 Modulators of ATP-Binding Cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-12 US disclosed
US-8614327-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-12-24 US disclosed
US-20130165442-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-27 US disclosed
US-8354427-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICAL INCORPORATED (US) 2013-01-15 US disclosed
US-20120309758-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-06 US disclosed
US-20100184739-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165442-A1 Modulators of ATP-Binding Cassette Transporters CFTR, ABCB1, ABCC2 CYP1A2 2537/4885HSD17B10 1468/4885KDM4E 4262/4885
US-20100184739-A1 Modulators of ATP-Binding Cassette Transporters CFTR, ABCB1, ABCC2 CYP1A2 2537/4885HSD17B10 1468/4885KDM4E 4262/4885
US-20140343098-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 CYP1A2 2537/4885HSD17B10 1468/4885KDM4E 4262/4885
US-20120309758-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 CYP1A2 2537/4885HSD17B10 1468/4885KDM4E 4262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.